Skip to main content
. 2020 Sep 21;8(3):551. doi: 10.3390/vaccines8030551

Figure 3.

Figure 3

Agarose gel electrophoresis of a range of DNA:SLN-A weight ratios. (a) DNA binding assay: Lane 1—Hyperladder I, lane 2—plasmid DNA only, lane 3: SLN-A only, lane 4–8: 1:1, 1:5, 1:10, 1:50, 1:100 DNA:SLN weight ratio lipoplexes; (b) DNase I protection assay: Lane 1—Hyperladder I, lane 2—digested plasmid DNA, lane 3: SLN-A only, lane 4–8: 1:1, 1:5, 1:10, 1:50, 1:100 DNA:SLN weight ratio lipoplexes treated with DNase I and subsequently released from particles by SDS treatment.